ArticleDiscover oncology2025
A Mendelian randomization-based risk model using aging-related genes for prognosis in lung adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAging-related genes (ARGs) are prognostic markers in cancers, but their role in lung adenocarcinoma (LUAD) remains unclear. Investigating ARGs in LUAD may provide valuable insights for clinical diagnosis and treatment.
methodsGene expression profiles from TCGA and GEO datasets were analyzed to identify ARG-related genes. Univariate Cox regression and LASSO analysis were used to construct a prognostic risk model. Kaplan-Meier survival analysis, ROC curves, and clinicopathological features validated its predictive accuracy. Immune cell infiltration and tumor microenvironment were assessed using CIBERSORT and ESTIMATE. RT-qPCR was used to validate the differential expression of key genes in LUAD and adjacent normal tissues.
resultsSeven prognostic ARGs (RHPN2, BLK, PTPRO, CA4, UBE2C, METTL7A, and H2BC12) were identified. The risk model stratified patients into high- and low-risk groups, with high-risk individuals showing poorer survival, increased immune evasion, and altered immune cell infiltration. These findings were validated in independent datasets. RT-qPCR confirmed elevated RHPN2, BLK, UBE2C, and H2BC12 in tumors, while PTPRO, CA4, and METTL7A were reduced.
conclusionA robust ARG-based risk model, leveraging Cox regression and LASSO, effectively predicts survival and immunotherapy responses in LUAD, offering new tools for personalized prognosis and treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.